NewcelX Ltd.
NCEL evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for NCEL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NCEL
NewcelX Ltd. is a clinical-stage biopharmaceutical company developing off-the-shelf cell therapies for neurodegenerative diseases and type 1 diabetes, with no revenue to date and a going concern uncertainty.
Key risk: Going concern uncertainty
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2025.
NewcelX Ltd. is a clinical-stage biopharmaceutical company developing off-the-shelf cell therapies for neurodegenerative diseases and type 1 diabetes, with no revenue to date and a going concern uncertainty.
- NewcelX is a clinical-stage biopharmaceutical company with a platform for off-the-shelf cell-based products [sec · filed 2026-04-29].
- As of December 31, 2025, the company had cash & equivalents of $2.2M, a net loss of $8.3M, negative shareholders' equity of $1.2M, and total debt of $2.6M [sec].
- The company has incurred significant operating losses since inception and has not generated any revenue from product candidates [sec · filed 2026-04-29].
- Its portfolio includes AstroRx® (Phase IIa for ALS) and NCEL-101 (Phase I for type 1 diabetes) [sec · filed 2026-04-29].
- NewcelX's current cash on hand is not sufficient to fund projected operating requirements, raising substantial doubt about its ability to continue as a going concern [sec · filed 2026-04-29].
What works
- NewcelX has a unique platform for off-the-shelf cell therapy targeting unmet medical needs [sec · filed 2026-04-29].
- The company has two product candidates in clinical development: AstroRx® (Phase IIa for ALS) and NCEL-101 (Phase I for type 1 diabetes) [sec · filed 2026-04-29].
- NewcelX is also advancing a preclinical program for narcolepsy under its DOXA platform [sec · filed 2026-04-29].
What to weigh
- NewcelX has no revenue and expects to continue incurring losses for the foreseeable future [sec · filed 2026-04-29].
- The company's current cash is insufficient to fund operations, creating substantial doubt about its ability to continue as a going concern [sec · filed 2026-04-29].
- Clinical development is lengthy and expensive, and there is no assurance of regulatory approval for any product candidate [sec · filed 2026-04-29].
- NewcelX's financial position may require additional capital sooner than planned, with uncertainties around funding [sec · filed 2026-04-29].
From the filings
Quoted directly from source documents.
NewcelX has not generated any revenue from product candidates.
“To date, NewcelX has not generated any revenue from NewcelX's development stage product candidates, AstroRx® and/or INCEL-101.”
SEC filings · April 29, 2026
Current cash is insufficient to fund operations, raising going concern doubt.
“NewcelX does not believe that its current cash on hand will be sufficient to fund its projected operating requirements. This raises substantial doubt about its ability”
SEC filings · April 29, 2026
NewcelX has incurred significant operating losses since inception.
“NewcelX has incurred significant operating losses since NewcelX's inception and anticipates that NewcelX will incur continued losses for the foreseeable future.”
SEC filings · April 29, 2026
The company's portfolio includes AstroRx® and NCEL-101.
“NewcelX's portfolio comprises a clinical program, AstroRx ® , human astrocytes derived from pluripotent stem cells for the treatment of neurodegenerative diseases such as ALS, as well as a preclinical proof of concept program,”
SEC filings · April 29, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Cash on hand is insufficient to fund projected operating requirements, raising substantial doubt about ability to continue [sec · filed 2026-04-29].
- No revenue and continued losses — No revenue generated to date; expects continued losses for the foreseeable future [sec · filed 2026-04-29].
- Regulatory approval risk — No assurance that any product candidate will receive regulatory approval necessary for commercialization [sec · filed 2026-04-29].
- Clinical trial delays — Clinical development is lengthy and expensive with uncertain timelines and outcomes [sec · filed 2026-04-29].
What to watch
- Funding and capital-raising activities to address the going concern uncertainty [sec · filed 2026-04-29].
- Clinical trial progress for AstroRx® (Phase IIa for ALS) and NCEL-101 (Phase I for type 1 diabetes) [sec · filed 2026-04-29].
- Regulatory developments, including interactions with EMA and FDA [sec · filed 2026-04-29].
- Ability to maintain Nasdaq listing compliance [sec · filed 2026-04-29].
Sources: SEC filings · Generated August 21, 2026 · How we verify sources →
Run NewcelX Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available NewcelX Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
2.7 months
D/E 0.58 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
2 buys · 0 sells (180d)
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1
Total value held
$6
| Holder | Shares | Value |
|---|---|---|
| corecap advisors, llc | 3 | $6 |
Frequently asked questions
What is the AI investment thesis for NewcelX Ltd.?
NewcelX Ltd. is a clinical-stage biopharmaceutical company developing off-the-shelf cell therapies for neurodegenerative diseases and type 1 diabetes, with no revenue to date and a going concern uncertainty.
Who is the CEO of NewcelX Ltd.?
Mr. Ronen Twito CPA is the chief executive officer of NewcelX Ltd. (NCEL).
Where is NewcelX Ltd. headquartered?
NewcelX Ltd. (NCEL) is headquartered in Kloten, Switzerland.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.